1283129-21-4

Basic information

• Product Name: 2,3,4,6-tetra-O-pivaloyl 1-(2,6-dimethoxyphenyl)-1-deoxy-β-D-glucopyranose
• Synonyms: 2,3,4,6-tetra-O-pivaloyl 1-(2,6-dimethoxyphenyl)-1-deoxy-β-D-glucopyranose
• CAS NO: 1283129-21-4
• Molecular Weight: 636.78
• Mol File: 1283129-21-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2,3,4,6-tetra-O-pivaloyl 1-(2,6-dimethoxyphenyl)-1-deoxy-β-D-glucopyranose(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,4,6-tetra-O-pivaloyl 1-(2,6-dimethoxyphenyl)-1-deoxy-β-D-glucopyranose(1283129-21-4)
• EPA Substance Registry System: 2,3,4,6-tetra-O-pivaloyl 1-(2,6-dimethoxyphenyl)-1-deoxy-β-D-glucopyranose(1283129-21-4)

Safety Data

• Hazardous Substances Data: 1283129-21-4(Hazardous Substances Data)

Upstream product

• 62955-29-7 C₁₆H₁₈O₄Zn 
• 81058-27-7 2,3,4,6-tetra-O-pivaloyl-α-D-glucopyranosyl bromide 
• 958300-05-5 2,3,4,6-tetra-O-pivaloyl-β-D-glucopyranosylbromide 

Relevant articles and documents

Exploiting Synergistic Effects in Organozinc Chemistry for Direct Stereoselective C-Glycosylation Reactions at Room Temperature

Pairing a range of bis(aryl) zinc reagents ZnAr2 with the stronger Lewis acidic [(ZnArF2)] (ArF=C6F5), enables highly stereoselective cross-coupling between glycosyl bromides and ZnAr2 without the use of a transition metal. Reactions occur at room temperature with excellent levels of stereoselectivity, where ZnArF2 acts as a non-coupling partner although its presence is crucial for the execution of the C(sp2)–C(sp3) bond formation process. Mechanistic studies have uncovered a unique synergistic partnership between the two zinc reagents, which circumvents the need for transition-metal catalysis or forcing reaction conditions. Key to the success of the coupling is the avoidance of solvents that act as Lewis bases versus diarylzinc compounds (e.g. THF).

PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT2

The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.